One of the most powerful and elite investment groups is ready to
launch yet another company to be profiled. These are the individuals
who have been on top of HTDS and BIEL during their 1000%+ gains in the
past, and now comes a new stock with similar potential. It follows in
those foot steps in that it is one of the top heavily shorted
companies, it is within the small cap medical industry, and has
recently released results for the third quarter. During this current
period, the company reported increased revenues of nearly 100% from
the same quarter last year, and as well managed to decrease expenses
by over 50% during that same period.
News is coming, are YOU ready for the company?

Join us at http://groups.google.com/group/market-mafia

GLTA!

I believe people still have fresh memory of OPXA which created another
myth of stock market of 2009 by jumping from $0.5 to more than $6 in
one month. It is almost as incredible as CTIC.

If you take a close look of MBRX and OPXA, you will find that they
have so many similarities before the OPXA-Novartis deal was reached.

1, they both have low stock price and market capital what make them
attractive for big drug makers.
2, hardly maintain their operations and researches what make them more
willing to sell themselves.
3, promising novel technologies and pipeline what are the key point to
make the deal happen.

Now let’s have quick look of MBRX’s product candidates and
technologies

MBRX currently have four product candidates at the clinical stage of
development. These product candidates include the metabolic disease
proprietary product candidates, MB07811 and MB07803, which have been
developed as potential treatments for hyperlipidemia, and type 2
diabetes, respectively, and the liver disease proprietary product
candidates, , which have been developed as potential treatments for
hepatitis B and primary liver pradefovir and MB07133 cancer,
respectively. In addition, MBRX has compounds generated from various
advanced research programs, such as the glucagon antagonist program.

Hyperlipidemia, diabetes, hepatitis B and liver cancer are all main
diseases which threaten lives of human being, and any single drugs has
billion dollars potential market.

Technology:
MRBX have extensive expertise in liver diseases and in the pathways
and proteins residing in the liver that are involved in certain
metabolic diseases. The company has two proprietary discovery
platforms, HepDirect® and NuMimetic™, which the company have used to
develop the current product candidates and which are expected to be
used to expand the product pipeline in the future.

*HepDirect: Pradefovir, MB07133 and MB07811 use HepDirect technology,
as do several research programs. In addition to MBRX’s internal
programs, the company has worked with Merck and Idenix to discover
treatments for hepatitis C by seeking to liver-target compounds they
have designated. MBRX may similarly leverage this technology with
other companies.

*NuMimetic technology: MBRX have developed a library of unique
molecules, known as nucleotide mimetics, and have used this library to
discover compounds that the company believes have the potential to
treat metabolic diseases. MBRX used NuMimetic technology to discover
CS-917 and MB07803, and the company is also using it in certain of
their advanced research programs including the AMPK discovery project
which is conducting with Merck.

These two technologies alone are attractive enough for an acquisition
besides MBRX’s robust pipeline.

Can MBRX develop these product candidates and technologies by herself?
I hope MBRX could make it independently but the company already gave
out the answer in the quarterly report:

All research and development activities of MBRX were discontinued for
the purpose of cash reserve.

Based on the current operating plan, after considering the impact of
these recent transactions, together with the cash available at June
30, 2009, MBRX’s working capital will fund the current operating plan
through December 2009.（P18, Liquidity and Capital Resources）

The company has about 6.6 million dollars on the balance sheet and is
expecting to receive about 1.5 million dollars for the laboratory and
equipment sale in this month.

We can tell that MBRX is ready to welcome a merger.

So why I mention Roche?

MBRX currently maintains a Research Collaboration and License
Agreement with Roche. The Company’s HepDirect™ liver-targeted
technology is applied to proprietary Roche compounds to develop
second-
generation nucleoside analog drug candidates for treating hepatitis C
virus. The Company will be eligible to receive up to $191.0 million in
additional payments upon achievement of predetermined preclinical and
clinical development events as well as regulatory and
commercialization events.

MBRX already received a non-refundable upfront payment of $10.0
million from Roche in August 2008. (10-Q P13)
It is not hard to find out that it is more feasible for Roche to take
over MBRX instead of paying 100 of million dollars milestone EXCLUDE
royalty.

If not Roche, are there any other giants that can possibly lend MBRX a
hand?

The 7th Annual Pharmaceutical-Biotech Partnering Conference will be
held during Oct. 5-7. MBRX will attend this conference and we expect
that the company can demonstrate her leading technologies and product
candidates and attract other attendees like GSK, Eli Lilly, Novartis,
Abbott Laboratories and so forth.

Will MBRX realize a deal like OPXA? I am pretty positive of this.
Let’s wait and see.

* Statement: The author of this article is not a licensed analyst and
the purpose of this article is for information sharing and discussion
only, not recommendation for any stock buying, selling and shorting
activities. Please do your own research before making any trading
decision.

the lagre institutions can see as high as 70 before september . Tis is
not fantasy. It is possible to see above one hundred new buble stock.

may be a potential short  http://tinyurl.com/bujk2q

Fact #1 since Sept. 3, 2008 SIGA has secured $79,618,000 in funding
for development of it's drug pipeline.

*BREAKDOWN*

$20,000,000 Sept 18

$3,655,000 Sept 15

$963,000 Sept. 12

$55,000,000 Sept. 3

Fact #2 on Sept 2 SIGA's share price closed at $3.77 The above funding
news is not priced in at all, YET! The value of such funding is
delayed in terms of stock price only because the large players gather
as many shares cheap as can be shaken from weak hands. The step of
gathering shares is near completion. Will you risk missing the large
run when at this price it's well bellow value?

Fact #3 BARDA & National Institute of Allergy & Infectious Diseases
(NIAID) will for emergency stockpiling of ST-246 contract for
$300,000,000 - $500,000,000. Contracts this size have moved other like
stocks well over $22 a share, in fact the $79,618,000 should have run
SIGA to the $10 area.

Fact#4 The true value of a companies stock will always be valued in,
just not as soon as the smaller players want it because they always
want immediate results & that is just not the nature of the game. This
is a controlled game & big money controls!

Fact #5 The rise will happen before the end of October on a likely
Emergency contract for stockpile.

Not even listed is the fact SIGA is a potential buyout target. SIGA
Tech. is now testing a commercial anti-viral pipleline & when that
news leaks it will be a real gold rush. You must understand why SIGA
sits on that news (It's related to buyout patrons). It's all good load
while this is under $5, in fact this is cheap all under $6 due to
recent news.

A wonderful article in the world renowned SCIENCE magazines reveal the
best secrets of the drug ST-246. Yes, the little boy is doing great,
has returned home and hasn't lost any of his body skin. The drug is
not only super safe but its very potent and right on target. Here is
the link to the article.

http://www.sciencemag.org/cgi/content/full/316/5830/1418?maxtoshow=&H...

The Phase I trials are going great and results announcement is
imminent. The US CDC is ready to write a check of hundreds of millions
of $$ to stockpile this important drug as a part of their BIOShield
Program. Stay tuned, pile on this stock while its available at a great
discount and you will make a fortune when news is out.

A wonderful article in the world renowned SCIENCE magazines reveal the
best secrets of the drug ST-246. Yes, the little boy is doing great,
has returned home and hasn't lost any of his body skin. The drug is
not only super safe but its very potent and right on target. Here is
the link to the article.

http://www.sciencemag.org/cgi/content/full/316/5830/1418?maxtoshow=&H...

The Phase I trials are going great and results announcement is
imminent. The US CDC is ready to write a check of hundreds of millions
of $$ to stockpile this important drug as a part of their BIOShield
Program. Stay tuned, pile on this stock while its available at a great
discount and you will make a fortune when news is out.

http://www.sciencemag.org/cgi/content/full/316/5830/1418?maxtoshow=&H...

this stock has been declined for couple days. Is there any potential
that will go up again??

Because this is a manipulated stock with no fundamentals.  hudson
securities is the only market maker and they basically call the
shots.  All the press releases are fakes. But the SEC does not do
anything because they do not have the manpower to handle every single
case of fraud or alleged fraud.  Lick your wounds and move on.  This
will go to 1 or 2 in about a year.

Anyone know why in the past two days why SIGA has taken a 10% nose
dive?  I heard that their results from the second qtr testing was
positive and that the news was going to be coming out beginning of
Sept.  This should be a time of loading up on the stock but with its
sharp decline, I'm sure its scaring investors away...

man, you rock, hahahaha

because it is manipulated by hudson securities.  The smart money gets
out after some press release that makes the shares fly.  then they buy
when it hits bottom and release some bogus press release and send the
shares soaring. and they do this over and over again.

sounds like urban legend.